Pharmaceutical company Galderma has announced a net sale of $2.448 billion for the first half of 2025 and 12.2% year-on-year growth.
Galderma reported growth in all major categories and a double-digit increase in dermatological skincare and injectable aesthetics subcategories.
The company announced that there was especially strong growth for injectable aesthetics in the UK, achieving a 9.8% increase, with dermatological skincare growing by 7.7% and therapeutic dermatology increasing by 26.9%.
Momentum in product innovation Nemluvio (nemolizumab) was also reported by Galderma, delivering $131 million in sales, and filler brand Relfydess expanded to 17 markets.
Flemming Ørnskov, CEO at Galderma, said, “Galderma’s strong performance in the first half of 2025 underscores the impact of our executional excellence across product categories and the continued ramp-up of our two potential blockbuster launches. Reflecting this strong progress and confidence in the business, we are raising our full-year guidance on net sales.”